cisplatin + bleomycin + dacarbazine

Cisplatin + bleomycin + dacarbazine is an investigational or off-protocol combination chemotherapy regimen consisting of three cytotoxic small molecules: - **Cisplatin:** a platinum-based agent causing DNA crosslinking and apoptosis. - **Bleomycin:** an antitumor antibiotic that induces DNA strand breaks via free radical formation. - **Dacarbazine:** a triazene alkylating agent, cytotoxic through DNA methylation and inhibition of DNA synthesis. While all three drugs are used in standard regimens for treating cancers such as lymphoma, germ cell tumors, and melanoma, there is limited evidence for clinical use as a specific three-drug combination distinct from more common and standard regimens (such as ABVD, BEACOPP, or cisplatin-vinblastine combinations)[3][4][5][6][7][8][1][2]. This regimen may act synergistically through complementary but non-overlapping **DNA-damaging mechanisms**, and has primarily been explored in trials for metastatic melanoma and discussed as potential alternatives or explorative regimens in chemoresistant disease settings[1][2][4].